Maxim Group set a $25.00 target price on Coherus Biosciences (NASDAQ:CHRS) in a report published on Friday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.
Several other research firms have also recently weighed in on CHRS. Robert W. Baird set a $28.00 price target on Coherus Biosciences and gave the stock a buy rating in a research note on Wednesday, April 10th. Zacks Investment Research cut Coherus Biosciences from a hold rating to a sell rating in a research note on Monday, March 25th. ValuEngine cut Coherus Biosciences from a buy rating to a hold rating in a research note on Saturday, May 4th. BidaskClub raised Coherus Biosciences from a sell rating to a hold rating in a report on Thursday, January 31st. Finally, Credit Suisse Group set a $25.00 price objective on Coherus Biosciences and gave the stock a buy rating in a report on Thursday, March 7th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $28.00.
CHRS stock opened at $16.74 on Friday. Coherus Biosciences has a 1-year low of $8.32 and a 1-year high of $20.66. The company has a debt-to-equity ratio of 8.29, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market capitalization of $1.21 billion, a PE ratio of -5.20 and a beta of 3.64.
In related news, CFO Jean-Frederic Viret sold 3,000 shares of Coherus Biosciences stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $14.92, for a total value of $44,760.00. Following the completion of the sale, the chief financial officer now owns 13,185 shares of the company’s stock, valued at $196,720.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 18.20% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Trexquant Investment LP bought a new position in Coherus Biosciences in the first quarter worth approximately $290,000. Atika Capital Management LLC bought a new position in Coherus Biosciences in the first quarter worth approximately $2,564,000. The Manufacturers Life Insurance Company grew its stake in Coherus Biosciences by 6.8% in the first quarter. The Manufacturers Life Insurance Company now owns 34,519 shares of the biotechnology company’s stock worth $471,000 after purchasing an additional 2,186 shares in the last quarter. Northern Trust Corp grew its stake in Coherus Biosciences by 2.2% in the first quarter. Northern Trust Corp now owns 664,619 shares of the biotechnology company’s stock worth $9,065,000 after purchasing an additional 14,075 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its stake in Coherus Biosciences by 57.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 21,630 shares of the biotechnology company’s stock worth $295,000 after purchasing an additional 7,876 shares in the last quarter. 94.77% of the stock is owned by institutional investors.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Read More: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.